Delcath Systems (STU:DV3R) Asset Impairment Charge : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Delcath Systems Asset Impairment Charge?

Delcath Systems's Asset Impairment Charge for the three months ended in Mar. 2024 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Delcath Systems Asset Impairment Charge Historical Data

The historical data trend for Delcath Systems's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Delcath Systems Asset Impairment Charge Chart

Delcath Systems Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

Delcath Systems Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Delcath Systems Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Delcath Systems Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Delcath Systems's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Delcath Systems (STU:DV3R) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (STU:DV3R) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

DCTH:USA DV3R:Germany

Address

1633 Broadway, Suite 22C, New York, NY, USA, 10019

Website

https://www.delcath.com

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Delcath Systems (STU:DV3R) Headlines

No Headlines